ELDN
ELEDON (ELDN) Reports 24-Month Phase 2 Kidney Data and Wins FDA Fast Track
Tegoprubart kept kidney function about 13 mL/min/1.73 m² above tacrolimus at month 24, as Eledon prepares to start its Phase 3 LEGACY trial in Q4.
ELDN
Market-moving news on Eledon Pharmaceuticals (NASDAQ: ELDN): filings, earnings, deals and other events, from REDFILED.